Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Role Of Saccharomyces Boulardii in Preventin Necrotizing Enterocolitis in Very Low Birth Weight Infants
Brief Summary: Probiotics are favorable microorganisms that regulate the flora of the gastrointestinal system and stimulate the immune system. Necrotizing enterocolitis incidence is 10-25% in newborn infants whose birth weights are \< 1500 gr. Although bifidobacterium and lactobacilli sp. have been used to reduce the incidence of NEC in clinical trials, Saccharomyces boulardii has not been used in the prevention of NEC in very low birth weight infants yet. The objective of this study is to evaluate the efficacy of orally administered S boulardii in reducing the incidence and severity of NEC in very low birth weight infants.


Options:
A: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
B: Arm Label: Bifidobacterium lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis plus İnülin, Other: Maltodextrin, Dietary Supplement: İnulin | Arm Label: İnulin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis, Dietary Supplement: Bifidobacterium lactis plus İnülin, Other: Maltodextrin | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis, Dietary Supplement: Bifidobacterium lactis plus İnülin, Dietary Supplement: İnulin | Arm Label: Bifidobacterium lactis plus İnülin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis, Other: Maltodextrin, Dietary Supplement: İnulin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium lactis; Assigned to Arm(s): Bifidobacterium lactis plus İnülin, Maltodextrin, İnulin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium lactis plus İnülin; Assigned to Arm(s): Bifidobacterium lactis, Maltodextrin, İnulin | Intervention Type: OTHER; Name: Maltodextrin; Assigned to Arm(s): Bifidobacterium lactis, Bifidobacterium lactis plus İnülin, İnulin | Intervention Type: DIETARY_SUPPLEMENT; Name: İnulin; Assigned to Arm(s): Bifidobacterium lactis, Bifidobacterium lactis plus İnülin, Maltodextrin
C: Arm Label: Saccharomyces boulardii; Type: EXPERIMENTAL; Interventions: Drug: Saccharomyces boulardii | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): control
D: Arm Label: Main Study; Type: N/A; Interventions: N/A | Arm Label: Gestational Diabetes Mellitus Cohort; Type: N/A; Interventions: N/A | Arm Label: Fresh Milk Cohort; Type: N/A; Interventions: N/A | Arm Label: RNA Milk Fat Cohort; Type: N/A; Interventions: N/A | Arm Label: Skin Study; Type: N/A; Interventions: N/A | Arm Label: BMMI Project; Type: N/A; Interventions: N/A

Answer: C